INS and type 2 diabetes mellitus: According to European society for medical oncology (ESMO) guideline of management of toxicities from immunotherapy, asymptomatic cases or with mild symptoms of hyperglycemia (new onset immune-related DM or worsening T2DM) can continue ICIs therapy with close follow-up and take insulin replacement as default therapy.